7XP.F Organon & Co
- Market cap
- EUR 3.23B
- P/E
- 18.4x
- P/B
- 3.03x
- ROE
- 46.7%
- Dividend yield
- 0.58%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 7XP.F undervalued?
Graham number7XP.F trades 57.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Organon & Co fundamental analysis
No fundamental analysis for Organon & Co yet.
Organon & Co stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Organon & Co
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Merci…
Full company profileOrganon & Co financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Organon & Co annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | - | 9.78B | 9.53B | 8.10B | 6.30B | 6.17B | 6.26B | 6.40B | 6.22B | 6.12B |
| Gross Profit | - | 5.08B | 5.91B | 4.75B | 3.92B | 3.88B | 3.75B | 3.72B | 3.31B | 3.33B |
| Operating Income | - | 2.71B | 3.66B | 2.78B | 1.81B | 1.71B | 1.33B | 1.49B | 1.23B | 1.27B |
| EBITDA | - | 4.38B | 4.01B | 2.94B | - | 1.54B | 1.44B | 1.60B | 1.29B | 1.63B |
| Net Income | - | 2.15B | 3.22B | 2.16B | 1.35B | 917M | 1.02B | 864M | 187M | 557M |
| EPS | - | - | 13 | 8.53 | 5.33 | 3.60 | 4.00 | 3.35 | 0.72 | 2.12 |
| Balance Sheet | ||||||||||
| Total Assets | - | - | 10.5B | 10.4B | 10.7B | 11.0B | 12.1B | 13.1B | 12.9B | 13.4B |
| Total Liabilities | - | - | 3.51B | 11.3B | 12.2B | 11.8B | 12.1B | 12.6B | 12.1B | 12.2B |
| Shareholders' Equity | - | - | 7.04B | -820M | -1.51B | -892M | -70.0M | 472M | 752M | 1.19B |
| Cash & Short-term Investments | - | - | 319M | 500M | 737M | 706M | 693M | 675M | 574M | 1.46B |
| Cash Flow | ||||||||||
| Operating Cash Flow | 3.42B | 3.69B | 2.77B | 2.19B | 2.46B | 858M | 669M | 939M | 700M | 936M |
| Capital Expenditure | 86.0M | 101M | 92.0M | 255M | 192M | 196M | 245M | 351M | 316M | 223M |
| Free Cash Flow | - | 3.59B | 2.66B | 1.91B | 1.97B | 431M | 424M | 588M | 384M | 713M |
| Ratios | ||||||||||
| ROE | - | - | 45.7% | - | - | - | - | 183.1% | 24.9% | 46.7% |
| ROA | - | - | 30.5% | 20.7% | 12.6% | 8.4% | 8.5% | 6.6% | 1.5% | 4.2% |
| Net Profit Margin | - | 22.0% | 33.8% | 26.7% | 21.4% | 14.9% | 16.3% | 13.5% | 3.0% | 9.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Organon & Co dividends
- Dividend yield
- 0.58%
- Forward dividend
- 0.07 EUR
- Payout ratio
- 47.1%
- Ex-dividend date
- Nov 9, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 88.0M | 0.34 | 47.1% |
| 2024 | USD 297M | 1.15 | 34.4% |
| 2023 | USD 294M | 1.15 | 28.7% |
| 2022 | USD 290M | 1.14 | 31.6% |
| 2021 | USD 145M | 0.57 | 10.7% |
| 2020 | USD 145M | 0.57 | 6.7% |
| 2019 | USD 145M | 0.57 | 4.5% |
| 2018 | USD 145M | - | 6.7% |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Organon & Co
- Insiders 0.46%
- Institutions 86.67%
- Public & others 12.86%
- Shares outstanding 263M
- Free float 243M
Organon & Co company profile
- Company name
- Organon & Co
- Ticker
- 7XP.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 10,000
- Fiscal year end
- December
- Address
- 30 Hudson Street, Jersey City, NJ, United States, 07302
- Phone
- 551 430 6900
- Website
- organon.com
About Organon & Co
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.
Organon & Co management
10- Ms. Carrie Smith CoxExecutive Chair of the Board · born 1959
- Mr. Joseph T. Morrissey Jr.Chief Executive Officer · born 1965
- Mr. Matthew M. Walsh C.F.A.Executive VP & CFO · born 1967
- Ms. Rachel A. StahlerExecutive VP, Chief Information Officer and Chief Digital & Growth Officer · born 1976
- Mr. Kirke WeaverExecutive VP, General Counsel & Corporate Secretary · born 1973
- Dr. Juan Camilo Arjona Ferreira M.D.Executive VP, Head of Research & Development and Chief Medical Officer · born 1970
- Ms. Jennifer HalchakHead of Investor Relations
- Mr. Daniel KarpChief Strategy Officer & Head of Corporate Development · born 1978
- Mr. Aaron FalcioneExecutive VP & Chief Human Resources Officer · born 1971
- Mr. Vittorio NisitaExecutive VP and Head of Enterprise Services & Solutions · born 1968